Products

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recombinant Canine Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13), N-His

Name: Recombinant Canine Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13), N-His
SKU: AP7F329
Rating: 5 (1 reviews)

Cat. No.AP7F329

Product TypeAnimal Proteins

Size

Inquiry Now Add to Basket

Product Overview

BioVenic's Recombinant Canine Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13), N-His is a recombinant protein expressed from E.coli expression system. Its predicted molecular weight is 24.8 kDa. The purity is>97% (SDS-PAGE). The endotoxin level is <1 EU/μg (LAL). It can be used as a positive control or as an immunogen.

Specifications

Type Recombinant Protein

Species Canine

Expression System E.coli

Purity >97% (SDS-PAGE)

Endotoxin <1 EU/μg (LAL)

Predicted Molecular Weight 24.8 kDa

Molecular Weight 28 kDa

Physical State Lyophilized

Formulation 20 mM Tris, 150 mM NaCl, pH 8.0, containing 0.01% SKL, 5% Trehalose.

Target Information

The proliferation-inducing ligand (APRIL), alternatively named tumor necrosis factor ligand superfamily member 13 (TNFSF13), is a TNF superfamily protein identified by the cell surface receptor TACI.

Protein Canine Tumor Necrosis Factor Ligand Superfamily, Member 13 (TNFSF13)

Protein Synonym TNF superfamily member 13; TNFSF13; proliferation-inducing ligand; APRIL

Shipping and Storage

This product is shipped with dry ice. Avoid repeated freezing and thawing. Store for 4 weeks at 2-8°C, for 12 months at -80°C.

Documents

Datasheet

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

User Note

Always centrifuge tubes before opening. Avoid mixing by vortexing or pipetting. Reconstitute in ddH2O to a concentration of 0.1-0.25 mg/mL. Do not vortex. Aliquote the reconstituted solution to minimise freeze-thaw cycles.